FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to compounds of formula (l) and their pharmaceutically acceptable salts wherein X represents CH or N; one of R1 and R2 represents H and the other one is specified in OR6, SR6, Me, Et and SOR8; R3 is specified in tert-butylmethyl, sec-butyl, tert-butyl, cyclopentyl and cyclohexyl; R4 cyclopentyl C1-8alkyl optionally substituted by one C1-6alkoxy group; or C3-8cycloalkyl optionally substituted by one C1-6alkoxy group; R6 represents C1-8alkyl; and R8 represents C1-8alkyl, as well as to based pharmaceutical compositions and applying them as cathepsin K inhibitors and for analysing the cathepsin K inhibitors specified above.
EFFECT: there are presented new biologically active compounds and using them in medicine and pharmaceutics.
12 cl, 79 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | 2014 |
|
RU2678327C2 |
SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | 2013 |
|
RU2654482C2 |
CARBAPENEM COMPOUNDS | 2017 |
|
RU2772909C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
COMPOUND, PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITION OF HIV-PROTEASE ACTIVITY | 1994 |
|
RU2139280C1 |
SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
MACROCYCLIZATION REACTIONS AND INTERMEDIATE COMPOUNDS AND OTHER FRAGMENTS SUITABLE FOR PREPARING ANALOGUES OF HALICHONDRIN B | 2014 |
|
RU2710545C2 |
Authors
Dates
2012-07-20—Published
2007-07-13—Filed